ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.652,67
0,44%
S&P 500
5.352,96
-0,02%
Dow Jones
38.886,17
0,20%
Euro vs US Dollar
1,08925
0,17%
Bitcoin
70.796,07
-0,40%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) News

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:IBRX
DatumZeitQuelleÜberschriftSymbolFirma
17/05/202415h00Business WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastNASDAQ:IBRXImmunityBio Inc
09/05/202423h00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
07/05/202414h00Business WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®NASDAQ:IBRXImmunityBio Inc
02/05/202422h04Business WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesNASDAQ:IBRXImmunityBio Inc
30/04/202414h00Business WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationNASDAQ:IBRXImmunityBio Inc
25/04/202406h03Business WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerNASDAQ:IBRXImmunityBio Inc
23/04/202403h56Business WireImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:IBRXImmunityBio Inc
06/03/202415h00Business WireNIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral TherapyNASDAQ:IBRXImmunityBio Inc
05/03/202415h00Business WireN-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure StudyNASDAQ:IBRXImmunityBio Inc
26/02/202422h43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
26/02/202422h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
26/02/202422h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
24/02/202403h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
21/02/202415h00Business WireImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the TrialNASDAQ:IBRXImmunityBio Inc
07/02/202403h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
05/02/202415h00Business WireImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCGNASDAQ:IBRXImmunityBio Inc
03/02/202401h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
03/02/202401h33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
04/01/202403h59Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:IBRXImmunityBio Inc
04/01/202403h41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
04/01/202403h40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
02/01/202412h08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
02/01/202412h00Business WireImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 MillionNASDAQ:IBRXImmunityBio Inc
16/11/202315h00Business WireImmunityBio to Participate in 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:IBRXImmunityBio Inc
09/11/202303h28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
07/11/202315h00Business WireFirst Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor ActivityNASDAQ:IBRXImmunityBio Inc
26/10/202318h03Dow Jones NewsImmunityBio Shares Rally as FDA Accepts N-803 ResubmissionNASDAQ:IBRXImmunityBio Inc
26/10/202315h00Business WireFDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA DateNASDAQ:IBRXImmunityBio Inc
23/10/202317h00Dow Jones NewsImmunityBio Shares 11% Higher on License Application Resubmission for N-803NASDAQ:IBRXImmunityBio Inc
23/10/202315h00Business WireImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-SituNASDAQ:IBRXImmunityBio Inc
 Showing the most relevant articles for your search:NASDAQ:IBRX

Kürzlich von Ihnen besucht

BITMOT
813684
Eib Tf 1,125% Ap33 Eur
USOTC
BGNRF
Blackgold Natural Resour... (CE)
EU
CADCT
Caisse Amort Dette Socia...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten